Rosenblatt reiterates Roku [ROKU] rating to Buy and sets new price target at $400
Rosenblatt maintained its Roku [ROKU] rating to the equivalent of Buy but changed the price target to $420.0 from $260, in a research note dated 2021-01-08. That figure represents around a 10.73% premium from where the company’s shares closed on Thursday. Other analysts also revised their coverage, with Wells Fargo’s analysts reiterating the shares to […]
Brown & Brown [BRO] gets an upgrade to a Buy from Goldman Sachs
Goldman Sachs took its Brown & Brown [BRO] rating to the equivalent of Buy from Neutral, and the price target to $54.0 from $49, in a research note dated 2021-01-08. That figure represents around a 12.76% premium from where the company’s shares closed on Thursday. Other analysts also revised their coverage, with Morgan Stanley’s analysts […]
How come Cullinan Management, Inc.’s (CGEM) stock is performing so well right now?
Cullinan Management, Inc. (CGEM) stock soared 33.33% to $28.00 as the biotech company announced the pricing of its upsized initial public offering that will distribute 11,900,000 shares of the Company’s common stock to the public at a price of $21.00 per share. Before deducting underwriting discounts, commissions, and other offering expenses, Cullinan Management expects to […]
CVS Health [CVS] gets an upgrade to a Buy from Jefferies
Jefferies took its CVS Health [CVS] rating to the equivalent of Buy from Hold, and the price target to $90.0, in a research note dated 2021-01-08. That figure represents around a 21.62% premium from where the company’s shares closed on Thursday. Some new analysts also started their coverage, with Piper Sandler’s analysts assigning the shares […]
CareTrust REIT [CTRE] Stock Gets an Upgrade from BMO Capital. It’s Now Outperform
BMO Capital took its CareTrust REIT [CTRE] rating to the equivalent of Outperform from Market Perform, and the price target to $26.0, in a research note dated 2021-01-08. That figure represents around a 18.75% premium from where the company’s shares closed on Thursday. Other analysts also revised their coverage, with KeyBanc Capital Markets’s analysts upgrading […]
Wells Fargo lowers Amphastar Pharmaceuticals [AMPH] rating to Equal-Weight and sets price target at $21
Wells Fargo took its Amphastar Pharmaceuticals [AMPH] rating to the equivalent of Equal-Weight from Overweight, and the price target to $21.0, in a research note dated 2021-01-08. That figure represents around a 1.69% premium from where the company’s shares closed on Thursday. Other analysts also revised their coverage, with Northland Capital’s analysts upgrading the shares […]
Is this what has driven BIONANO GENOMICS, (BNGO) shares down today?
The biotechnology company BIONANO GENOMICS, INC. (Nasdaq: BNGO) stock plummet today as it was trading down -19.20% to $4.04, as the company announced that it had priced its previously announced public offering of 29,016,393 shares of its common stock at $3.05 per share. In the face of underwriting discounts and commissions and estimated offering expenses, […]
Piper Sandler lifts Chevron [CVX] rating to Overweight and price target to $113
Piper Sandler took its Chevron [CVX] rating to the equivalent of Overweight from Neutral, and the price target to $113.0, in a research note dated 2021-01-08. That figure represents around a 25.21% premium from where the company’s shares closed on Thursday. Other analysts also revised their coverage, with Wells Fargo’s analysts downgrading the shares from […]
Arthur J. Gallagher [AJG] Downgraded to Neutral at Goldman Sachs
Goldman Sachs took its Arthur J. Gallagher [AJG] rating to the equivalent of Neutral from Buy, and the price target to $129.0 from $123, in a research note dated 2021-01-08. That figure represents around a 5.41% premium from where the company’s shares closed on Thursday. Some new analysts also started their coverage, with Evercore ISI’s […]
Tesla [TSLA] Stock Gets an Upgrade from Evercore ISI Group. It’s Now In-Line
Evercore ISI Group took its Tesla [TSLA] rating to the equivalent of In-Line from Underperform, and the price target to $650.0, in a research note dated 2021-01-08. That figure represents around a -20.35% premium from where the company’s shares closed on Thursday. Other analysts also revised their coverage, with Morgan Stanley’s analysts reiterating the shares […]
